CLOV RSI Chart
Last 7 days
2.5%
Last 30 days
-17.2%
Last 90 days
-18%
Trailing 12 Months
-12.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 3.1B | 2.8B | 2.4B | 2.0B |
2022 | 2.1B | 2.6B | 3.0B | 3.5B |
2021 | 707.7M | 948.1M | 1.2B | 1.5B |
2020 | 514.9M | 567.6M | 620.2M | 672.9M |
2019 | 0 | 0 | 0 | 462.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 15, 2024 | soares karen | sold (taxes) | -4,134 | 0.8 | -5,168 | general counsel & secretary |
Mar 15, 2024 | reynoso jamie l. | sold (taxes) | -4,302 | 0.8 | -5,378 | ceo, medicare advantage |
Mar 14, 2024 | reynoso jamie l. | sold (taxes) | -5,677 | 0.73 | -7,777 | ceo, medicare advantage |
Mar 14, 2024 | wai conrad | sold (taxes) | -54,309 | 0.73 | -74,396 | chief technology officer |
Mar 14, 2024 | loengard anna u | bought | 9,946 | 0.73 | 13,625 | - |
Mar 14, 2024 | loengard anna u | bought | 100,010 | 0.73 | 137,000 | - |
Feb 14, 2024 | soares karen | sold (taxes) | -5,719 | 0.95 | -6,020 | general counsel & secretary |
Feb 09, 2024 | sharp aric r | sold (taxes) | -8,431 | 1.02 | -8,266 | ceo of value based care |
Feb 08, 2024 | toy andrew | sold (taxes) | -85,367 | 1.00 | -85,367 | chief executive officer |
Jan 25, 2024 | leffler scott j. | sold (taxes) | -81,867 | 0.98 | -83,538 | chief financial officer |
Which funds bought or sold CLOV recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | unchanged | - | -654,165 | 4,865,350 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -20.87 | -10,041,100 | 23,166,200 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 95.77 | 443,641 | 1,054,850 | -% |
Feb 23, 2024 | Chicago Partners Investment Group LLC | sold off | -100 | -15,693 | - | -% |
Feb 16, 2024 | O'Dell Group, LLC | new | - | 58.00 | 58.00 | -% |
Feb 16, 2024 | HARBOUR INVESTMENTS, INC. | unchanged | - | -10.00 | 71.00 | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | reduced | -9.4 | -60,000 | 240,000 | 0.02% |
Feb 15, 2024 | Legal & General Group Plc | unchanged | - | -34,588 | 257,466 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 738 | 450,000 | 520,000 | -% |
Feb 15, 2024 | State of Wyoming | added | 35.78 | 61,196 | 371,889 | 0.07% |
Unveiling Clover Health Investments, Corp.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to Clover Health Investments, Corp.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 454.6B | 371.6B | 20.31 | 1.22 | ||||
CI | 106.2B | 195.3B | 19.78 | 0.54 | ||||
CVS | 100.0B | 357.8B | 11.97 | 0.28 | ||||
HCA | 87.7B | 65.0B | 16.74 | 1.35 | ||||
CNC | 41.9B | 154.0B | 15.51 | 0.27 | ||||
UHS | 12.6B | 14.3B | 17.56 | 0.88 | ||||
DVA | 12.0B | 12.1B | 17.36 | 0.99 | ||||
MID-CAP | ||||||||
CHE | 9.7B | 2.3B | 35.74 | 4.3 | ||||
ACHC | 7.2B | 2.9B | -333.68 | 2.47 | ||||
AMN | 2.3B | 3.8B | 11.05 | 0.61 | ||||
AMEH | 2.3B | 1.4B | 37.6 | 1.65 | ||||
SMALL-CAP | ||||||||
ADUS | 1.7B | 1.1B | 26.93 | 1.59 | ||||
BKD | 1.2B | 3.0B | -6.6 | 0.41 | ||||
BEAT | 56.3M | - | -3.85 | - | ||||
AMS | 16.9M | 20.7M | 83.48 | 0.82 |
Clover Health Investments, Corp. News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Revenue | 5.8% | 510,251 | 482,066 | 513,628 | 527,775 | 898,791 | 856,817 | 846,700 | 874,379 | 432,036 | 427,163 | 412,472 | 200,325 | 166,233 | 169,069 | 172,081 | 165,505 | - |
Gross Profit | -1.3% | 62,266 | 63,107 | 76,674 | 55,285 | 5,146 | 17,018 | -12,086 | 12,657 | - | -9,162 | -46,031 | - | - | - | - | - | - |
Operating Expenses | 10.0% | 575,911 | 523,535 | 542,435 | 600,381 | 1,005,411 | 930,913 | 949,427 | 961,860 | 618,825 | 576,416 | 594,334 | 319,413 | 233,862 | 190,687 | 148,911 | 192,135 | - |
S&GA Expenses | 8.0% | 45,080 | 41,747 | 42,433 | 59,215 | 55,348 | 47,832 | 47,040 | 57,697 | 55,177 | 45,846 | 45,646 | 38,618 | 41,032 | 29,847 | 21,468 | 28,483 | - |
Interest Expenses | - | - | - | 7.00 | - | 136 | 404 | 390 | 403 | 403 | 404 | 1,211 | 1,175 | 10,430 | 9,268 | 8,477 | 7,815 | - |
Net Income | -69.9% | -70,472 | -41,469 | -28,814 | -72,606 | -83,503 | -75,489 | -104,362 | -75,490 | -187,201 | -34,527 | -317,611 | -48,417 | -126,391 | 12,758 | 5,403 | -28,162 | -17.63 |
Net Income Margin | -12.2% | -0.10* | -0.09* | -0.09* | -0.11* | -0.10* | -0.15* | -0.16* | -0.29* | -0.40* | -0.44* | -0.51* | -0.22* | -0.20* | -0.02* | -0.64* | -0.71* | -0.79* |
Free Cashflow | -1103.9% | -229,031 | -19,024 | 52,819 | 78,781 | -213,245 | 101,396 | -39,344 | -57,200 | -80,414 | -45,321 | -64,346 | -92,968 | -59,967 | -34,817 | 13,011 | -37,418 | - |
Balance Sheet | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Assets | -46.2% | 571 | 1,060 | 1,258 | 1,454 | 809 | 1,558 | 2,063 | 2,680 | 951 | 952 | 1,216 | 867 | 267 | 829 | 829 | 583 | 337 |
Current Assets | -53.3% | 428 | 916 | 1,129 | 1,274 | 625 | 1,460 | 1,861 | 2,491 | 753 | 559 | 718 | 809 | 190 | 1.00 | 1.00 | - | 253 |
Cash Equivalents | -41.0% | 176 | 299 | 310 | 191 | 104 | 383 | 324 | 274 | 300 | 202 | 486 | 405 | 92.00 | 90.00 | 107 | 112 | 68.00 |
Net PPE | 11.2% | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | - | - | - | 2.00 |
Liabilities | -61.5% | 284 | 738 | 927 | 1,130 | 452 | 1,166 | 1,636 | 2,190 | 411 | 540 | 901 | 278 | 433 | 31.00 | 29.00 | - | 378 |
Current Liabilities | -63.7% | 261 | 719 | 908 | 1,110 | 432 | 1,128 | 1,599 | 2,152 | 372 | 230 | 196 | 173 | 164 | 2.00 | 0.00 | 1.00 | 142 |
Long Term Debt | - | - | - | - | - | - | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 5.00 | 106 | - | - | - | 58.00 |
LT Debt, Non Current | - | - | - | - | - | - | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 24.00 | 106 | - | - | - | 58.00 |
Shareholder's Equity | -11.0% | 286 | 322 | 331 | 323 | 357 | 392 | 427 | 490 | 540 | 412 | 315 | 589 | 5.00 | 5.00 | 5.00 | 0.00 | - |
Retained Earnings | -3.4% | -2,159 | -2,089 | -2,047 | -2,019 | -1,946 | -1,871 | -1,796 | -1,692 | -1,616 | -1,429 | -1,395 | -1,077 | -1,028 | -2.37 | -0.07 | -0.02 | -891 |
Additional Paid-In Capital | 1.4% | 2,461 | 2,428 | 2,395 | 2,359 | 2,319 | 2,281 | 2,238 | 2,195 | 2,154 | 1,839 | 1,706 | 1,663 | 412 | 7.00 | 5.00 | 0.00 | 403 |
Shares Outstanding | -100.0% | - | 481 | - | 479 | 476 | 476 | 475 | 473 | 413 | 415 | 395 | 376 | 89.00 | 89.00 | 89.00 | 88.00 | 88.00 |
Minority Interest | - | - | - | - | - | - | - | - | - | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | -1120.9% | -229,295 | -18,781 | 53,173 | 79,032 | -209,368 | 101,655 | -39,171 | -57,042 | -80,176 | -45,126 | -64,155 | -92,869 | -59,904 | -34,650 | 13,232 | -37,176 | -17.63 |
Share Based Compensation | 0.2% | 33,136 | 33,070 | 36,108 | 38,617 | 39,094 | 42,644 | 41,927 | 40,640 | 31,181 | 46,803 | 43,026 | 42,713 | 2,129 | 1,501 | 1,471 | 1,977 | - |
Cashflow From Investing | 511.7% | 83,662 | -20,321 | 66,491 | 10,181 | 12,656 | -43,389 | 89,353 | 36,513 | -106,491 | -242,345 | 170,865 | -257,476 | 67,557 | 1,500 | -14,163 | 82,510 | - |
Cashflow From Financing | -1408.8% | -29,617 | -1,963 | -147 | -2,134 | 56.00 | 132 | 458 | -5,608 | 284,371 | 3,988 | -25,470 | 662,504 | -5,037 | 15,470 | -4,151 | -438 | 18.00 |
Buy Backs | -58.5% | 827 | 1,994 | 417 | 2,982 | 42.00 | 276 | 105 | 5,939 | - | 147 | - | - | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) | 12 Months Ended | ||||
---|---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |||
Revenues: | |||||
Premiums earned, net (Net of ceded premiums of $444, $470, and $489 for the years ended December 31, 2023 and 2022, and 2021 respectively) | $ 1,235,769,000 | $ 1,084,869,000 | $ 799,414,000 | ||
Non-Insurance revenue | 773,177,000 | 2,380,135,000 | 667,639,000 | ||
Other income | 24,774,000 | 11,683,000 | 4,943,000 | ||
Total revenues | 2,033,720,000 | 3,476,687,000 | 1,471,996,000 | ||
Operating expenses: | |||||
Net medical claims incurred | 1,776,388,000 | 3,453,952,000 | 1,551,178,000 | ||
Salaries and benefits | 257,157,000 | 278,725,000 | 260,458,000 | ||
General and administrative expenses | 187,571,000 | 207,917,000 | 185,287,000 | ||
Impairment of goodwill and other intangible assets | 15,945,000 | 0 | 0 | ||
Premium deficiency reserve expense (benefit) | (7,239,000) | (93,517,000) | 110,628,000 | ||
Depreciation and amortization | 2,509,000 | 1,187,000 | 1,246,000 | ||
Restructuring costs | 9,931,000 | 0 | 0 | ||
Other expense | 0 | 70,000 | 191,000 | ||
Total operating expenses | 2,242,262,000 | 3,848,334,000 | 2,108,988,000 | ||
Income (loss) from operations | (208,542,000) | (371,647,000) | (636,992,000) | ||
Change in fair value of warrants | 86,000 | (900,000) | (66,146,000) | ||
Interest expense | 7,000 | 1,333,000 | 3,193,000 | ||
Amortization of notes and securities discounts | 0 | 30,000 | 13,717,000 | ||
Loss (gain) on investment | 4,726,000 | (9,217,000) | 0 | ||
Gain on extinguishment of note payable | 0 | (23,326,000) | 0 | ||
Net loss | $ (213,361,000) | $ (339,567,000) | $ (587,756,000) | ||
Per share data: | |||||
Net loss per share attributable to Class A and Class B common stockholders - basic (in dollars per share) | [1] | $ (0.44) | $ (0.71) | $ (1.42) | |
Net loss per share attributable to Class A and Class B common stockholders - diluted (in dollars per share) | [1] | $ (0.44) | $ (0.71) | $ (1.42) | |
Weighted average number of common shares outstanding | |||||
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares) | [1] | 482,176,127 | 476,244,262 | 412,922,424 | |
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares) | [1] | 482,176,127 | 476,244,262 | 412,922,424 | |
Net unrealized gain (loss) on available-for-sale investments | $ 7,004,000 | $ (7,440,000) | $ (1,944,000) | ||
Comprehensive loss | $ (206,357,000) | $ (347,007,000) | $ (589,700,000) | ||
|
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 122,863 | $ 103,791 |
Short-term investments | 12,218 | 41,457 |
Investment securities, available-for-sale (Amortized cost: 2023: $101,412; 2022: $193,300) | 100,702 | 189,498 |
Investment securities, held-to-maturity (Fair value: 2023: $6,778; 2022: $15) | 6,902 | 15 |
Accrued retrospective premiums | 22,076 | 20,387 |
Other receivables | 16,666 | 23,596 |
Healthcare receivables | 64,164 | 70,607 |
Non-Insurance receivable | 10,926 | 52,955 |
Surety bonds and deposits | 55,631 | 100,502 |
Prepaid expenses | 14,418 | 18,146 |
Other assets, current | 1,404 | 4,043 |
Total current assets | 427,970 | 624,997 |
Investment securities, available-for-sale (Amortized cost: 2023: $121,868; 2022: $142,940) | 120,208 | 137,368 |
Investment securities, held-to-maturity (Fair value: 2023: $692; 2022: $636) | 793 | 742 |
Property and equipment, net | 5,082 | 5,753 |
Operating lease right-of-use assets | 3,382 | 4,025 |
Goodwill and other intangible assets | 2,990 | 20,000 |
Other assets, non-current | 10,246 | 15,735 |
Total assets | 570,671 | 808,620 |
Current liabilities | ||
Unpaid claims | 138,593 | 141,947 |
Non-Insurance performance year obligation, current | 15,568 | 73,844 |
Non-Insurance payable | 41,565 | 148,191 |
Accounts payable and accrued expenses | 37,184 | 32,445 |
Accrued salaries and benefits | 21,061 | 23,962 |
Deferred revenue | 3,099 | 0 |
Operating lease liabilities | 1,665 | 1,827 |
Premium deficiency reserve | 0 | 7,239 |
Total current liabilities | 261,115 | 431,507 |
Long-term operating lease liabilities | 2,998 | 4,033 |
Other liabilities, non-current | 20,164 | 16,193 |
Total liabilities | 284,277 | 451,733 |
Commitments and Contingencies (Note 19) | ||
Stockholders' equity | ||
Additional paid-in capital | 2,461,238 | 2,319,157 |
Accumulated other comprehensive loss | (2,370) | (9,374) |
Accumulated deficit | (2,159,794) | (1,946,433) |
Less: Treasury stock, at cost; 7,912,750 and 2,072,752 shares held at December 31, 2023 and December 31, 2022, respectively | (12,729) | (6,509) |
Total stockholders' equity | 286,394 | 356,887 |
Total liabilities and stockholders' equity | 570,671 | 808,620 |
Common Class A | ||
Stockholders' equity | ||
Common stock, value | 40 | 37 |
Common Class B | ||
Stockholders' equity | ||
Common stock, value | 9 | 9 |
Related party | ||
Current liabilities | ||
Due to related parties, net | 1,363 | 1,566 |
Other liabilities, current | 1,363 | 1,566 |
Nonrelated Party | ||
Current liabilities | ||
Due to related parties, net | 1,017 | 486 |
Other liabilities, current | $ 1,017 | $ 486 |
 | Mr. Andrew Toy |
---|---|
 | www.cloverhealth.com |
 | 656 |